cemka > Publications > Oncology

Sort publications on year

  • Biometry and database analysis

    Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.

    HARROW B, FAGNANI F, NEVORET C, TRUONG-THANH XM, DE ZÉLICOURT M, DE MESTIER L.

    Adv Ther ; 2022;39:1754-1771

  • Biometry and database analysis

    Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: A nationwide retrospective analysis.

    NEUZILLET C, EMERY C, TEISSIER C, BOUEE S, LIEVRE A.

    Lancet Reg Health Eur ; 2022;15:100324

  • Biometry and database analysis

    Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study

    GIRARD N, MORO-SIBILOT D, BOUEE S, EMERY C, TORRETON E, LE LAY K, LUCIANI L, MARITAZ C, CHOUAID C

    Future Oncol ; 2020;16(16),1115-1124

  • Pharmaco-Economics

    Absenteeism and indirect costs during the year following the diagnosis of an operable breast cancer: A prospective multicentric cohort study

    FERRIER C, THEBAUT C, BAFFERT S, ASSELAIN B, ROUZIER R,HEQUET D

    J Gynecol Obstet Hum Reprod ; 2020(Online)

  • Biometry and database analysis

    Effectiveness of sequencing TKIs in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC): A French national medical-administrative claim database analysis

    GIRARD N, BOUEE S, MORO-SIBILOT D, EMERY C, LE LAY K, LUCIANI L, MARITAZ C, CHOUAID C

    Annals of Oncology ; 2019;30(5):v627-v628

  • Pharmaco - Epidemiology

    Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study

    GIRARD N, MORO-SIBILOT D, BOUEE S, EMERY C, TORRETON E, LE LAY K, LUCIANI L, MARITAZ C, CHOUAID C.

    Future Oncol ; 2020;16(16),1115-1124

  • Pharmaco-Economics

    Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study

    HEQUET D, HUCHON C, SOILLY AL, ASSELAIN B, BERSENEFF H, TRICHOT C, COMBES A, ALVES K, NGUYEN T, ROUZIER R, BAFFERT S.

    PLoS One ; 2019;14(7)

  • Biometry and database analysis

    Economic burden of chemotherapy-treated recurrent and/or metastatic squamous cell carcinoma of the head and neck in france: real world data from the permanent sample of national health insurance beneficiairies.

    LAFUMA A, COTTÉ FE, LE TOURNEAU C, EMERY C, GAUDIN AF, TORRETON E, GOURMELEN J, BONASTRE J.

    J Med Econ ; 2019

  • Pharmaco-Economics

    Cost-effectiveness of web-based patient-reported outcome surveillance in lung cancer patients.

    LIZÉE T, BASCH E, TRÉMOLIÈRES P, VOOG E, DOMONT J, PEYRAGA G, URBAN T, BENNOUNA J, SEPTANS A-L, BALAVOINE M, DETOURNAY B, DENIS F.

    J Thorac Oncol ; 2019;14(6):1012-1020

  • Pharmaco-Economics

    Determinants of return at work of breast cancer patients: results from the OPTISOINS01 French prospective study

    ARFI A, BAFFERT S, SOILLY AL, HUCHON C, REYAL F, ASSELAIN B, NEFFATI S, ROUZIER R, HÉQUET D.

    BMJ Open ; 2018;8(5):e020276

  • Public Health and Epidemiology

    Un outil de suivi et d’auto-évaluation du bon usage du médicament en cancérologie : l’observatoire du médicament d la FNCLCC

    LATOUR JF, GAMEROFF S, GENEVE J, FAGNANI F

    J Pharm Clin ; 26(3):151-157

  • Pharmaco-Economics

    Evaluation économique du trastuzumab en traitement adjuvant du cancer du sein précoce surexprimant HER2

    FAGNANI F, COLIN X, ARVEUX P, COUDERT B, MISSET JL

    Bulletin du Cancer ; 94(7):711-720

  • Pharmaco-Economics

    Invasive cervical cancer treatment costs in France

    ARVEUX P, BENARD S, BOUEE S, LAFUMA A, MARTIN L, CRAVELLO L, REMY V, BREUGELMANS JG

    Bull Cancer ; 94(2):219-224

  • Pharmaco-Economics

    Coût de la prise en charge des frottis anormaux et des néoplasies intraépithéliales du col de l’utérus en France

    BERGERON C, COHET C, BOUEE S, LORANS C, REMY V

    BEH ; (1):4-6

  • Pharmaco-Economics

    Cost Consequences of Adjuvant Capecitabine, Mayo Clinic and de Gramont Regimens for Stage III Colon Cancer in the French Setting

    DOUILLARD JY, TILLEUL P,YCHOU M, DUFOUR P, PERROCHEAU G, SEITZ JF, MAES P, LAFUMA A, HUSSEINI F

    Oncology ; 72:248-254